Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TG Therapeutics ( (TGTX) ) just unveiled an update.
On January 13, 2026, TG Therapeutics reported unaudited preliminary results showing U.S. BRIUMVI net product revenue of about $182 million for the fourth quarter of 2025 and $594 million for the full year, contributing to approximately $616 million in total global revenue for 2025, underscoring rapid commercial traction in the multiple sclerosis market since launch. For 2026, the company is targeting total global revenue of roughly $875 million to $900 million, driven largely by anticipated U.S. BRIUMVI sales of $825 million to $850 million, alongside planned operating expenses of about $350 million (excluding non-cash compensation) and roughly $100 million tied to scaling subcutaneous BRIUMVI manufacturing, while advancing a series of pivotal and exploratory clinical milestones intended to expand BRIUMVI’s use, support a subcutaneous and consolidated IV dosing strategy, and progress its azer-cel CAR-T program in autoimmune disease, which together aim to reinforce TG Therapeutics’ growth profile and broaden its autoimmune franchise.
The most recent analyst rating on (TGTX) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.
Spark’s Take on TGTX Stock
According to Spark, TipRanks’ AI Analyst, TGTX is a Neutral.
The score is driven primarily by improving fundamentals and a positive earnings-call outlook (strong BRIUMVI demand and raised guidance), tempered by weak cash flow quality (negative operating/free cash flow) and bearish technicals with the stock trading below key moving averages. Valuation is a supporting factor due to the low P/E.
To see Spark’s full report on TGTX stock, click here.
More about TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for autoimmune diseases, with a primary emphasis on multiple sclerosis (MS). Its lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody indicated for adults with relapsing forms of MS, and the company is exploring additional formulations and indications, including uses beyond MS and in autoimmune diseases more broadly.
Average Trading Volume: 1,824,059
Technical Sentiment Signal: Sell
Current Market Cap: $4.52B
See more data about TGTX stock on TipRanks’ Stock Analysis page.